“High LDL cholesterol is not harmful and may be protective, so lowering it is unnecessary.”
An editorial question about whether high LDL cholesterol is harmful and whether lowering it is needed.
Australian Prescriber describes LDL cholesterol as a causal risk factor for atherosclerotic cardiovascular disease, supported by genetic studies, prospective cohorts and randomised trials. It reports that each 1 mmol/L reduction is associated with a 21–25% lower relative risk of cardiovascular events. A meta-analysis of 20 cohort studies also found higher cardiovascular-event risk at LDL-C levels of 130 mg/dL or more, while LDL-C below 70 mg/dL was not associated with excess mortality or cardiovascular events compared with 70–129 mg/dL. Cohort associations cannot by themselves establish causation.
It can be confusing to hear conflicting claims about cholesterol. What have you heard about LDL, and would it help to discuss how your overall cardiovascular risk affects decisions about treatment?
Managing hypercholesterolaemia · Source document
The source exceeds the research excerpt. Check the full linked document before drawing clinical conclusions. The source exceeds the research excerpt. Check the full linked document before drawing clinical conclusions.
Time to lower LDL cholesterol targets after cardiac events · Source document
The source exceeds the research excerpt. Check the full linked document before drawing clinical conclusions.
Evidence checked November 04, 2026 · Reviewed November 04, 2026
Curated topic researched on demand from indexed public sources, not platform-wide monitoring. Attention and prevalence are not measured; the claim itself is editorial. Some searches or retrievals failed; review the research scope before publishing.
What changed
November 04, 2026 Australian Prescriber describes LDL cholesterol as a causal risk factor for atherosclerotic cardiovascular disease, supported by genetic studies, prospective cohorts and randomised trials. It reports that each 1 mmol/L reduction is associated with a 21–25% lower relative risk of cardiovascular events. A meta-analysis of 20 cohort studies also found higher cardiovascular-event risk at LDL-C levels of 130 mg/dL or more, while LDL-C below 70 mg/dL was not associated with excess mortality or cardiovascular events compared with 70–129 mg/dL. Cohort associations cannot by themselves establish causation.
November 03, 2026 An Australian Prescriber review describes LDL cholesterol as a causal risk factor for atherosclerotic cardiovascular disease, drawing on genetic, cohort and randomised-trial evidence. It reports that each 1 mmol/L reduction is associated with a 21–25% relative reduction in future atherosclerotic events. A meta-analysis of 20 cohort studies also found higher cardiovascular risk with LDL-C of 130–159 mg/dL and ≥160 mg/dL than with 70–129 mg/dL. Its observational design cannot establish cause and effect.
GPT-6 Luna The supplied evidence does not support the claim that high LDL is protective or that lowering it is unnecessary. The strongest source synthesises several types of evidence for a causal role and benefit from lowering LDL. Treatment decisions still depend on a person’s overall cardiovascular risk; these documents do not establish that every person needs the same target or treatment.
DeepSeek V4.1 Flash The claim is not supported. All three documents describe LDL cholesterol as causally implicated in atherosclerosis, with Mendelian randomisation and trials showing that lowering LDL-C reduces cardiovascular events. The meta-analysis found LDL-C of 130 mg/dL or higher associated with higher all-cause mortality and cardiovascular risk; it did not show harm from low LDL-C. No document supports a protective effect. Limitations: these are cohorts, a review and an opinion piece, not a dedicated trial of the claim. Applies to adults; targets are for high-risk and secondary prevention.
Grok 4.7 The claim is not supported. Australian and trial evidence treat high LDL cholesterol as causal in atherosclerosis. Lowering it reduces heart attack, stroke, and cardiovascular death, with about a 20 to 25 percent relative-risk reduction per 1 mmol/L fall. Very low achieved levels have not shown harm in major treatment trials. Some observational cohorts report higher all-cause mortality at low LDL, but that does not show high LDL is protective or make lowering unnecessary. Benefit is greatest after atherosclerotic events; targets and combinations should follow guidelines and individual risk, not be stopped abruptly.
